awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q47250599-3C96EEC6-E8BC-4244-BB4E-51BEB9C586B7
Q47250599-3C96EEC6-E8BC-4244-BB4E-51BEB9C586B7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47250599-3C96EEC6-E8BC-4244-BB4E-51BEB9C586B7
Emergence of a Promising Lead Compound in the Treatment of Triple Negative Breast Cancer: An Insight into Conformational Features and Ligand Binding Landscape of c-Src Protein with UM-164.
P2860
Q47250599-3C96EEC6-E8BC-4244-BB4E-51BEB9C586B7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47250599-3C96EEC6-E8BC-4244-BB4E-51BEB9C586B7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2168a611aae03ea2f25b501c240c63446fe7f366
P2860
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.